Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases (IMAGE)
Caption
According to the collaboration agreement, the two parties will jointly advance the co-development of the R&D program by combining Insilico Medicine’s validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS’s experienced R&D team and deep therapeutic expertise. Insilico Medicine is eligible to receive up to approximately 1.2 billion RMB in milestone payments plus royalties. This partnership marks a deepening collaboration that leverages both parties’ complementary strengths across the full value chain—from drug discovery and clinical development to commercialization.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content